Abivax: Biotech hope with strong seasonal tailwind
Reading Time: 3 minutes
Abivax is a French-American biotech company developing drugs for chronic inflammatory diseases. At the core is Obefazimod, an orally administered drug candidate aimed at stabilizing the immune response through the activation of microRNA-124. The primary target market is moderate to severe ulcerative colitis, a chronic intestinal disease characterized by high levels of suffering and a significant need for effective, well-tolerated therapies. Additionally, Abivax is evaluating Obefazimod for Crohn's disease and exploring the potential of the mechanism...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
